Views & Analysis Increasing access to medicines: A critical look at pharmaceu... Extending patents is restricting patients’ access to the treatments they need.
Views & Analysis Making the case for pharmaceutical IP management IP management can protect pharma companies’ investments and future R&D.
Views & Analysis Recent trends in ANDA litigation Sheila Swaroop and Kaitlin Heinen examine the findings of a recent report.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.